Session

Back to Programme Overview

Current tools for modern staging of urothelial tumours

Poster Session 32

  • Location:
    Room Stockholm (Hall B2, level 0)
  • Chairs:
     M.J. Ribal, Barcelona (ES)
     P. Black, Vancouver (CA)
     M. Roscigno, Vignate (IT)
  • Aims and objectives of this session

    Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous entity including different substages of superficial tumours with specific evolution and prognosis. The risks of recurrence and progression in NMIBC are largely influenced by well-known risk factors, such as stage, grade, multifocality, tumour size and concomitant CIS Thus, risk tables and scoring systems have been developed by the EORTC group to adapt the treatment to the aggressiveness of the disease. The current session is dedicated to current staging of urothelial tumours.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
392
New pathological features predicting prognosis of early-invasive urothelial carcinoma: Quantitative substaging and tumour invasion pattern should assist WHO 1973 grading classification in predicting cancer-specific survival of stage pT1 bladder cancer

By: Breyer J.1, Bertz S.2, Müller A.2, Lausenmeyer E-M.1, Mayr R.1, Gierth M.1, Burger M.1, Denzinger S.1, Hartmann A.2, Otto W.1

Institutes: 1University of Regensburg, Dept. of Urology, Regensburg, Germany, 2University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany

393
Associations of mutation heterogeneity in 20 cancer-related genes with the progression in T1G3 bladder cancers

By: Salomo K.1, Hübner D.1, Hahm J.2, Meinel J.3, Novotny V.1, Boehme M.2, Füssel S.1, Wirth M.1

Institutes: 1Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Urology, Dresden Johannstadt Nord, Germany, 2Biotype Diagnostic GmbH, Dept. of Research and Development, Dresden, Germany, 3Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Pathology, Dresden Johannstadt Nord, Germany

* 394
MRNA-based subtype classification of bladder cancer and patient outcome after radical cystectomy

By: Sjödahl G.1, Kollberg P.2, Liedberg F.1, Höglund M.3

Institutes: 1Lund University, Dept. of Translational Medicine, Malmö, Sweden, 2Lund University, Dept. of Translational Medicine, Helsingborg, Sweden, 3Dept. of Clinical Sciences Lund University, Dept. of Oncology, Lund, Sweden

395
Novel circulating tumour cell enumeration and epithelial/mesenchymal probe marking technique in bladder cancer

By: Chen H., Zhang R., Jin D., Dong L., Yang G., Cao M., Zhang L., Xue W., Huang Y.

Institutes: Shanghai Renji Hospital, Dept. of Urology, Shanghai, China

396
Impact of stage migration on bladder cancer: A slow but steady improvement in the long term survival rates after radical cystectomy in the last 25 years

By: Moschini M.1, La Croce G.1, Bianchi M.1, Cucchiara V.1, Freschi M.2, Burgio G.3, Shariat S.4, Serretta V.5, Damiano R.6, Briganti A.1, Montorsi F.1, Colombo R.1, Gallina A.1

Institutes: 1Uri, Irccs San Raffaele Scientific Institute, Dept. of Oncology and Urology, Milan, Italy, 2Uri, Irccs San Raffaele Scientific Institute, Dept. of Pathology, Milan, Italy, 3Uri, Irccs San Raffaele Scientific Institute, Dept. of Urology and Experimental Oncology, Milan, Italy, 4Medical University of Vienna, Dept. of Urology, Vienna, Austria, 5Università Degli Studi Di Palermo, Dept. of Discipline and Surgical Oncology, Palermo, Italy, 6Magna Græcia University of Catanzaro, Dept. of Urology and Doctorate Research Program, Catanzaro, Italy

397
Change of perioperative lymphocyte–monocyte ratio is good predictor of prognosis in patients with bladder cancer undergoing radical cystectomy

By: Kinoshita H., Yoshida T., Matsuda T.

Institutes: Kansai Medical University, Dept. of Urology and Andrology, Hirakata, Japan

398
Pelvic lymph node staging by combined 18F-FDG-PET/CT in bladder cancer following radical cystectomy

By: Pichler R.1, De Zordo T.2, Fritz J.3, Kroiss A.4, Heidegger I.1, Virgolini I.4, Aigner F.2, Uprimny C.4, Horninger W.1

Institutes: 1Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, 2Medical University Innsbruck, Dept. of Radiology, Innsbruck, Austria, 3Medical University Innsbruck, Dept. of Medical Statistics, Informatics and Health Economics, Innsbruck, Austria, 4Medical University Innsbruck, Dept. of Nuclear Medicine, Innsbruck, Austria

399
The timing of the TURBT and accuracy of bladder cancer staging

By: Robinson S.1, Bryan R.2, Maudgil D.3, Motiwala H.4, Montgomery B.4

Institutes: 1Frimley Park Hospital, Dept. of Urology, Henley on Thames, United Kingdom, 2University of Birmingham, The Institute of Cancer & Genomic Sciences, Birmingham, United Kingdom, 3Frimley Park Hospital, Dept. of Radiology, Frimley, United Kingdom, 4Frimley Park Hospital, Dept. of Urology, Frimley, United Kingdom

400
Preoperative platelet/leukocyte ratio and platelet count - impact on cancer-specific survival in patients undergoing radical cystectomy for bladder cancer

By: Schulz G.B., Grimm T., Buchner A., Schneevoigt B-S., Kretschmer A., Apfelbeck M., Grabbert M., Jokisch F., Stief C.G., Karl A.

Institutes: Ludwig-Maximilians University Munich, Dept. of Urology, Munich, Germany

401
MRI-based spatially resolved quantitative diffusivity measurements reflect proliferative activity of bladder cancer

By: Sevcenco S.1, Haitel A.2, Shariat S.3, Rauchenwald M.1, Klingler H-C.4, Susani M.2, Ponhold L.5, Baltzer P.5

Institutes: 1Sozialmedizinisches Zentrum Ost – Donauspital, Dept. of Urology, Vienna, Austria, 2Medical University of Vienna, Dept. of Histopathology, Vienna, Austria, 3Medical University of Vienna, Dept. of Urology, Vienna, Austria, 4Wilhelminenspital, Dept. of Urology, Vienna, Austria, 5Medical University of Vienna, Dept. of Radiology, Vienna, Austria

* 402
FDG PET-CT vs CT scan in the staging of urothelial neoplasms

By: Gaya Sopena J.M.1, Rodríguez O.1, Maroto P.2, Carrió I.3, Kanashiro A.1, Gómez De Liaño A.2, Palou J.1

Institutes: 1Universitat Autònoma de Barcelona – Fundació Puigvert, Dept. of Urology, Barcelona, Spain, 2Hospital De Sant Pau I La Santa Creu, Dept. of Oncology, Barcelona, Spain, 3Hospital De Sant Pau I La Santa Creu, Dept. of Nuclear Medicine, Barcelona, Spain

403
Apparent diffusion coefficient values obtained by unenhanced MRI predicts disease-specific survival in bladder cancer

By: Sevcenco S.1, Klingler H-C.2, Rauchenwald M.3, Haitel A.4, Shariat S.F.5, Maj-Hes A.5, Baltzer P.6

Institutes: 1Sozialmedizinisches Zentrum Ost – Donauspital, Dept. of Urology, Vienna, Austria, 2Wilhelminenspital, Dept. of Urology, Vienna, Austria, 3Sozialmedizinisches Zentrum Ost-Donauspital, Dept. of Urology, Vienna, Austria, 4Medical University of Vienna, Dept. of Histopathology, Vienna, Austria, 5Medical University of Vienna, Dept. of Urology, Vienna, Austria, 6Medical University of Vienna, Dept. of Radiology, Vienna, Austria

Summary and context
 P. Black, Vancouver (CA)